Brainstem glioblastoma multiforme in a patient with NF1

John T. Fortunato, Brian Reys, Pawan Singh, Edward Pan

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

This case report presents the first known case of a brainstem glioblastoma multiforme (GBM) in a patient with neurofibromatosis type 1 (NF1). While research has proposed that larger germ-line mutations in NF1 may be the driving factor that predisposes patients with NF1 to high-grade astrocytomas, this patient had a nonsense mutation in the NF1 gene, suggesting a variant tumorigenesis. Limited data on targeted immunotherapy for NF1 patients with a GBM have been reported and more data are required before targetedtherapies could be proven as second-line treatment options.

Original languageEnglish (US)
Pages (from-to)4897-4900
Number of pages4
JournalAnticancer Research
Volume38
Issue number8
DOIs
StatePublished - Aug 1 2018

Fingerprint

Neurofibromatosis 1
Glioblastoma
Brain Stem
Neurofibromatosis 1 Genes
Germ-Line Mutation
Nonsense Codon
Astrocytoma
Immunotherapy
Carcinogenesis
Research

Keywords

  • Brainstem
  • Glioblastoma multiforme
  • Immunotherapy
  • Neurofibromatosis type 1

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Brainstem glioblastoma multiforme in a patient with NF1. / Fortunato, John T.; Reys, Brian; Singh, Pawan; Pan, Edward.

In: Anticancer Research, Vol. 38, No. 8, 01.08.2018, p. 4897-4900.

Research output: Contribution to journalArticle

Fortunato, John T. ; Reys, Brian ; Singh, Pawan ; Pan, Edward. / Brainstem glioblastoma multiforme in a patient with NF1. In: Anticancer Research. 2018 ; Vol. 38, No. 8. pp. 4897-4900.
@article{23233f7290c44d10a92029b5781795cf,
title = "Brainstem glioblastoma multiforme in a patient with NF1",
abstract = "This case report presents the first known case of a brainstem glioblastoma multiforme (GBM) in a patient with neurofibromatosis type 1 (NF1). While research has proposed that larger germ-line mutations in NF1 may be the driving factor that predisposes patients with NF1 to high-grade astrocytomas, this patient had a nonsense mutation in the NF1 gene, suggesting a variant tumorigenesis. Limited data on targeted immunotherapy for NF1 patients with a GBM have been reported and more data are required before targetedtherapies could be proven as second-line treatment options.",
keywords = "Brainstem, Glioblastoma multiforme, Immunotherapy, Neurofibromatosis type 1",
author = "Fortunato, {John T.} and Brian Reys and Pawan Singh and Edward Pan",
year = "2018",
month = "8",
day = "1",
doi = "10.21873/anticanres.12804",
language = "English (US)",
volume = "38",
pages = "4897--4900",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "8",

}

TY - JOUR

T1 - Brainstem glioblastoma multiforme in a patient with NF1

AU - Fortunato, John T.

AU - Reys, Brian

AU - Singh, Pawan

AU - Pan, Edward

PY - 2018/8/1

Y1 - 2018/8/1

N2 - This case report presents the first known case of a brainstem glioblastoma multiforme (GBM) in a patient with neurofibromatosis type 1 (NF1). While research has proposed that larger germ-line mutations in NF1 may be the driving factor that predisposes patients with NF1 to high-grade astrocytomas, this patient had a nonsense mutation in the NF1 gene, suggesting a variant tumorigenesis. Limited data on targeted immunotherapy for NF1 patients with a GBM have been reported and more data are required before targetedtherapies could be proven as second-line treatment options.

AB - This case report presents the first known case of a brainstem glioblastoma multiforme (GBM) in a patient with neurofibromatosis type 1 (NF1). While research has proposed that larger germ-line mutations in NF1 may be the driving factor that predisposes patients with NF1 to high-grade astrocytomas, this patient had a nonsense mutation in the NF1 gene, suggesting a variant tumorigenesis. Limited data on targeted immunotherapy for NF1 patients with a GBM have been reported and more data are required before targetedtherapies could be proven as second-line treatment options.

KW - Brainstem

KW - Glioblastoma multiforme

KW - Immunotherapy

KW - Neurofibromatosis type 1

UR - http://www.scopus.com/inward/record.url?scp=85050829367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050829367&partnerID=8YFLogxK

U2 - 10.21873/anticanres.12804

DO - 10.21873/anticanres.12804

M3 - Article

C2 - 30061266

AN - SCOPUS:85050829367

VL - 38

SP - 4897

EP - 4900

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 8

ER -